Recent advances, patient selection & challenges in managing cancer patients undergoing treatment with immune checkpoint inhibitors

Indian J Med Res. 2022 Feb;155(2):219-224. doi: 10.4103/ijmr.ijmr_118_22.

Authors

Bernardo Leon Rapoport¹, Ronald Anderson²

Affiliations

¹ Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria; The Medical Oncology Centre of Rosebank, Johannesburg, South Africa.
² Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.

No abstract available

Publication types

Editorial

MeSH terms

Humans
Immune Checkpoint Inhibitors*
Immunotherapy / adverse effects
Neoplasms* / drug therapy
Patient Selection

Substances

Immune Checkpoint Inhibitors